Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

keratitis

- PMLiVE

The UK’s new Cancer Drugs Fund

"Clearer, faster decision-making" promised

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

- PMLiVE

NICE backs Xalkori for lung cancer, but may cut two others from CDF

Preliminary verdict could lead to removal of Novartis' Afinitor and Janssen's Imbruvica from the Fund

- PMLiVE

NICE backs use of AZ’s Brilique as maintenance therapy

Drug to be used with asprin as treatment for heart attack patients

- PMLiVE

NICE turns down CDF drug Adcetris in draft guidance

Takeda’s treatment for Hodgkin’s lymphoma not seen to be cost-effective

- PMLiVE

NICE swayed by extra data on Amgen’s Imlygic

Cost effectiveness watchdog backs immunotherapy in final draft guidance

Novartis Gehry Building

NICE backs Cosentyx for ankylosing spondylitis

The immunotherapy is on course to be “one of the most successful launches in Novartis history”

- PMLiVE

Rare blood cancer therapy Oncaspar gets NICE green light

Baxalta’s acute lymphoblastic leukaemia treatment recommended for NHS use

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Bristol-Myers Squibb (BMS) building

NICE finalises record-breaking Opdivo/Yervoy appraisal

BMS’s immunotherapy combination receives recommendation in 24 days

Bayer symbol

Xarelto leads the charge at Bayer

Impressive sales for the oral anticoagulant bolsters weaker crop science and animal health performance

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links